The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Merck said it expects the actions under the restructuring program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Federal vaccine advisors on Thursday recommended Merck's new RSV antibody shot for infants younger than eight months old in their first respiratory virus season, if their mother didn't receive a ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with a CAGR of 6.9%. Driven by ongoing health challenges, emerging trends ...

Scientists comment on Robert F. Kennedy Jr cancelling funding for mRNA vaccines. Prof Adam Finn, Professor of Paediatrics, University of Bristol, said: ...